導入
Penetratin Wholesale Bulk Peptide Two quotes arrive for the same 20-residue sequence. One is roughly a third of the other, and both suppliers appear competent. The instinct is to look for the catch — a hidden minimum, a lower purity grade, a missing certificate. Sometimes that is exactly what is happening. More often, the two documents are not quoting the same thing: different quantity basis, different analytical package, different counter-ion, different assumptions about what happens if synthesis underperforms.
This article works through five misconceptions that distort how buyers read peptide synthesis service price quotes, plus one counter-example where the usual per-milligram logic stops working. Each section names the faulty reasoning, gives the correction, and states what evidence would settle the question. No current prices are quoted as fact here; where a figure would be needed, it is left as a field to request. Research-grade peptides discussed throughout are laboratory reagents and are not intended for human use.
Misconception 1: “Price scales with residue count, so a 20-mer costs about twice a 10-mer”
The faulty reasoning. Many suppliers advertise a starting rate per amino acid residue, and buyers extrapolate: a 20-mer should cost about twice a 10-mer, and a 40-mer about twice a 20-mer. The rate is real, but it is a floor for standard sequences, not a linear predictor.
The correction. Residue count sets a baseline; sequence content sets the multiplier. Hydrophobic stretches, β-sheet-forming segments and aggregation-prone regions cause incomplete coupling on the resin, and the resulting deletion sequences have to be separated out or the batch resynthesized. あ でレビューする 生物工学とバイオテクノロジーのフロンティア on highly hydrophobic peptides documents the problem directly: aggregation on resin limits straightforward synthesis, and the field’s responses include pseudoprolines and O-acyl isopeptides to interrupt β-sheet formation, solubilizing tags, and native chemical ligation to assemble long or very hydrophobic targets from fragments. Fragment strategies and non-standard building blocks are additional chemical work, which is why they surface in price.
The linear assumption holds under a specific condition: short, 親水性の, unmodified sequences inside a supplier’s standard length range, where every coupling proceeds close to completion. Outside that range — long chains, multiple cysteines, dense hydrophobic runs — difficulty is sequence-specific and often only confirmed at synthesis, so a quote may carry a difficulty surcharge or a feasibility caveat rather than a flat per-residue rate.
What evidence settles it
Ask for a difficulty assessment or synthesis feasibility note covering the specific sequence, not just a per-residue rate. Whether a given supplier provides this as a standard deliverable varies; treat it as a question to confirm at quotation. A useful answer identifies the problematic region and states whether the quoted price assumes standard coupling or an adjusted route.
Misconception 2: “A 95% pure peptide means 95% of the powder is my peptide”
The faulty reasoning. A certificate reading “≥95% purity” is read as “95% of this vial is my peptide.” Buyers then calculate usable mass from the vial label and come up short at the bench.
Illustrative mass balance for a hypothetical 5 mg vial labeled ≥95% HPLC purity with 70% 正味ペプチド含有量. Both figures are assumed for the example and must be determined per lot; の 70% value is not a specification or a typical value for any particular sequence.
The correction. HPLC purity is a relative area percentage among detected peptide-related species. It says nothing about counter-ion, bound water or residual solvents. Net peptide content is the share of the lyophilized powder that is the target peptide, and the two numbers answer different questions. A supplier FAQ from PremierBiochem states that HPLC purity refers to the target peptide relative to peptide material only, not the entire lyophilized powder, and that net peptide content is typically 60–90%, obtainable by amino acid analysis or elemental analysis. That range is the supplier’s own statement and should be confirmed per lot, 想定されていない.
The mass-balance approach used for pharmacopoeial reference standards makes the arithmetic explicit. あ USP-authored paper on peptide reference standards (出版された 2023) describes subtracting all detectable non-peptide species — counter-ion, 水, 残留溶媒, residue on ignition — from 100% to assign purity, then assaying peptide mass per vial against that standard. The paper also notes that multiple methods exist for establishing peptide content and that approaches continue to evolve.
Hypothetical example (not a measured value). あ 5 mg vial labeled ≥95% HPLC purity with a reported net peptide content of 70% contains roughly 3.5 mg of target peptide. The arithmetic holds only if both figures are reported on the same basis and the net content is determined for that lot; a nominal 70% applied to a different sequence, counter-ion or water content will not transfer.
Misconception 3: “Modifications and salt form are add-ons that barely move the price”
The faulty reasoning. Buyers compare base synthesis prices and treat cyclization, リン酸化, labeling or a TFA-to-acetate exchange as minor line items that can be negotiated away later.
The correction. Each modification adds chemical steps, reagents and usually a separate analytical check, so it changes what is being quoted rather than just the total. の LifeTein custom peptide synthesis price page (日付なし; supplier marketing, used here only to show how items are structured) lists modification examples on a 20-mer — one disulfide bridge, two disulfide bridges, amide cyclization, single-site phosphorylation — as separately priced entries alongside the base synthesis tiers. That structure is the useful signal: modifications are itemized, not absorbed.
Salt form behaves the same way. JPT’s peptide quality page (undated supplier technical page) explains that peptides emerge from synthesis and purification as trifluoroacetate salts, that counter-ion exchange is sequence-dependent and requires optimized, sequence-specific protocols, and that post-exchange analysis is mandatory because partial decomposition may occur and residual TFA should be determined quantitatively. の 合成ペプチドの開発および製造に関するEMAガイドライン (EMA/CHMP/CVMP/QWP/367182/2025, 12月採択 2025, 効果的 1 6月 2026) lists counter-ion identity and content, residual TFA and water content among specification tests for synthetic peptides, and notes that counter-ion type can affect biological and physicochemical properties.
The impact on price depends on modification count, site and chemistry: a single phosphorylation is a different proposition from two disulfide bridges plus a non-natural residue. The condition to state in the RFQ is the exact modification map, so each supplier prices the same chemistry.
Misconception 4: “The cheapest per-milligram quote is the best value”
The faulty reasoning. Divide each quote by milligrams and pick the lowest number. This assumes the milligrams are equivalent and the surrounding deliverables are equivalent.
Recovery of a single 26-residue antimicrobial peptide from one laboratory, one gradient approach, by column diameter and crude load. Percentages are study-specific and should not be generalized to other sequences or suppliers.
The correction. Cost originates in four places — synthesis, 精製, quality control and delivery — and a per-milligram figure collapses all four into one number that may be computed on different bases. Purification alone is a real and variable cost driver. あ study of preparative reversed-phase HPLC collection efficiency (出版された 2007) purified a single 26-residue antimicrobial peptide on columns of different diameters: the semi-preparative column averaged 90.7% recovery across a 0.75–200 mg load range, while the microbore column recovered 78.0%, 88.1% そして 90.2% で 3.0, 1.5 そして 0.75 mg loads respectively, and only over a narrow load window. The scope matters: one peptide, one laboratory, one gradient approach. Those percentages should not be generalized to other sequences, but they show that yield — and therefore the crude mass needed per milligram delivered — depends on scale and setup.
Hypothetical comparison (both prices on request). Two quotes for the same 20-mer at “5 mg, ≥95%”: quote A states net peptide content, includes HPLC, MS and a lot-specific CoA, and specifies the counter-ion; quote B states neither net content nor counter-ion and lists HPLC only. The comparison fields, not the totals, decide which is cheaper per usable milligram. Request both quotes on the RFQ basis below before ranking them.
The counter-example: when per-milligram logic does not apply
Consider a hypothetical 1 mg request for an initial binding assay. Fixed setup, minimum order charges and QC documentation dominate the cost at this scale, so the per-milligram price is high while the absolute outlay is low — and ordering a larger vial to improve the unit price would leave most of the material unused and eventually degraded. Here the per-milligram metric misleads in the opposite direction.
The reverse case also exists: for a difficult hydrophobic sequence, an unusually low per-milligram quote may reflect a lower delivered net content or a resynthesis risk that has not been priced in. Minimum charges and scale breaks vary by supplier and must be confirmed at quotation; this scenario is illustrative, not a rate card.
Misconception 5: “Rework is the supplier’s problem, so I don’t need to ask about it”
The faulty reasoning. Buyers assume a failed synthesis is absorbed by the supplier, so rework terms are treated as boilerplate and skipped during comparison.
The correction. Contract terms vary, and they belong in the comparison before totals are ranked. AAPPTec’s published terms and conditions (undated supplier terms, cited as one example, not an industry standard) state that if the requested purity is not achieved or synthesis is unsuccessful, the seller will make reasonable additional attempts, including up to four re-synthesis or purification efforts where technically feasible; that the seller does not guarantee successful synthesis, final purity, 収率, biological activity or delivery timelines; that for multi-sequence orders the customer agrees to accept and pay for any peptides completed successfully regardless of the status of the remaining sequences; and that cancelling an order carries a 25% charge of order value. A supplier with different terms may carry more or less of that risk — and the price may reflect which.
Questions to confirm in writing: how many rework attempts are included, who bears the cost of each, what happens to partial multi-sequence orders, and whether a failed synthesis is refunded, credited or simply closed. The answers change the expected total cost of a difficult sequence even when the headline price is identical.
Making Quotes Comparable: An RFQ Field List
The five misconceptions collapse into one practical instrument: an RFQ that forces every quote アセチルヘキサペプチド 1 サプライヤー onto the same basis. Fill these fields once and send the same document to every supplier.
-
順序 in one-letter code, with N- and C-terminus stated (無料, acetylated, amidated).
-
Modification map: サイト, residue number and chemistry for each modification; disulfide pairing or cyclization pattern.
-
Target quantity, and whether it refers to powder mass or net peptide mass. Of Peptides Supplier
-
Purity target as HPLC area % and the method used to determine it.
-
正味ペプチド含有量 determination (アミノ酸分析 Peptides Hgh または元素分析) if usable mass matters to the assay.
-
対イオン形態: TFA, 酢酸塩または塩化物, with residual TFA limits if relevant.
-
分析パッケージ: HPLC, MS, ロット固有の CoA, and any additional identity tests.
-
Delivery format: lyophilized powder, aliquoting, sealing, shipping conditions.
-
Required turnaround and whether rush handling is priced separately. Ghrp 2 ペプチド
-
Rework and resynthesis terms, including attempt count and cost allocation.
-
Documentation and confidentiality 要件, including sequence version control.
MOL Changes provides custom peptide synthesis and modification services and invites project specifications for a scoped quotation. Prices and turnaround are confirmed per project; nothing in this article should be read as a published rate.
Two related topics worth reading next, if your program is moving toward documentation review: how to read a batch-specific certificate of analysis, and how sequence version control prevents non-reproducible experiments. Internal links are not supplied here because the site URLs were not provided.
Sources and Verification Notes
Primary and standards sources used for the claims above:
-
Mueller LK, Baumruck AC, Zhdanova H, Tietze AA. “Challenges and Perspectives in Chemical Synthesis of Highly Hydrophobic Peptides.” 生物工学とバイオテクノロジーのフロンティア, 2020. https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2020.00162/full
-
“Preparative reversed-phase HPLC collection efficiency for an antimicrobial peptide on columns of varying diameters.” ジャーナル オブ クロマトグラフィー A, issue dated 26 1月 2007. https://pmc.ncbi.nlm.nih.gov/articles/PMC2759115/
-
McCarthy D, Han Y, Carrick K, Schmidt D, Workman W, Matejtschuk P, Duru C, Atouf F. “Reference Standards to Support Quality of Synthetic Peptide Therapeutics.” 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10338602/
-
欧州医薬品庁. “Guideline on the Development and Manufacture of Synthetic Peptides,” EMA/CHMP/CVMP/QWP/367182/2025, 12月採択 2025, 効果的 1 6月 2026. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-development-manufacture-synthetic-peptides_en.pdf
Supplier pages used as leads or as examples of how one company structures its offer, not as market rates: JPT, “Peptide Quality & Purity” (日付なし), https://www.jpt.com/support-contact/resources/about-peptide-quality-purity/; PremierBiochem, “Peptide Synthesis FAQs” (日付なし), http://www.premierbiochem.com/Peptide-Synthesis-FAQs.html; AAPPTec, “Terms and Conditions” (日付なし), https://www.peptide.com/custom-peptide-company/terms-and-conditions/; LifeTein, “Custom Peptide Synthesis Service Price” (日付なし), https://www.lifetein.com/peptide-synthesis-price.html.
Evidence gaps. No independent market price survey was located, so no price range is asserted. Supplier pages carry no publication dates and their figures must be verified at quotation. The purification recovery percentages come from a single study of one peptide and should not be generalized. The 60–90% net peptide content range is a supplier statement, not a regulatory specification.
よくある質問
Why do two quotes for the same sequence differ so much? Usually because the documents differ in scope: quantity basis (powder mass versus net peptide), 純度法, counter-ion, analytical package, delivery terms or rework provisions. Ask each supplier to restate the quote against the RFQ fields above; if the gap persists after that, ask specifically which line item explains it.
Does higher HPLC purity mean more usable peptide per milligram? 必ずしもではありません. HPLC purity describes the target peptide relative to detected peptide-related species, while net peptide content describes how much of the powder is peptide after counter-ion, water and residual solvents are accounted for. Two vials at the same stated purity can deliver different usable masses if their net content differs. Request net peptide content when the assay depends on accurate mass.
Which sequence features make synthesis harder than residue count suggests? Hydrophobic runs, β-sheet-forming and aggregation-prone segments, multiple cysteines and long chains are the usual candidates, because they promote on-resin aggregation and incomplete coupling. Difficulty is sequence-specific and often confirmed only during synthesis, so ask for a feasibility note rather than assuming a per-residue rate applies.
What rework terms should be confirmed before comparing totals? The number of re-synthesis or purification attempts included, who bears the cost of each, how partial multi-sequence orders are handled, and whether cancellation carries a charge. Published terms differ between suppliers, so read them rather than assuming the supplier absorbs failed synthesis.
Next Step
The next round of quotes is only useful if it arrives on one basis. Take the RFQ field list above, fill in the sequence, modification map, quantity basis, 純度法, counter-ion and rework questions, and send the identical document to every supplier you are considering. Where a quote leaves a field blank, ask for that specific document — a lot-specific CoA, a net content determination, a feasibility note — rather than inferring the answer from the total.
If you have a defined sequence and specification, MOL Changes accepts project details for a scoped quotation covering custom synthesis and modification services, with analytical documentation matched to the requested package. Research-grade peptides are supplied for laboratory use and are not intended for human use.
開示: MOL Changes is a commercial peptide synthesis provider and has a business interest in the quality and documentation standards discussed in this article.
出版社の開示: MOL Changes はペプチド サービスを提供しており、このトピックに商業的関心を持っています。. サービス範囲と機能に関する記述はサプライヤーの主張です; 特定の構成の可用性とパフォーマンスにはプロジェクト固有の証拠が必要です.
